Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional adalimumab with endoscopic dilatation for intestinal strictures in Crohn's disease
2012-001723-12Phase 3Terminated
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Intralesional adalimumab + endoscopic dilatation with Intralesional placebo + endoscopic dilatation (2 arms). Primary endpoint: Success of endoscopic dilatation at week 8. Started Aug 2013; status: terminated.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2012-001723-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001723-12.